Biokine Therapeutics ^{For Profit}

Targeting Migration, Survival and Immune-response Pathways In cancer The Biokine Story Biokine Therapeutics is a private biopharmaceutical company founded in 2000. Biokine lead product BKT140/BL8040, is a high affinity, long-acting CXCR4 receptor inhibitor that already passed successful Phase III for Stem Cell Mobilization and Phase I/II for Immunotherapy for cancer together